Creams containing thyroid hormone are commonly employed for cosmetic purposes. To verify whether T 4 applied to the skin surface can enter the bloodstream either directly or as a metabolite, a cream containing L-T 4 [3,5,3,5-tetraiodothyronine (T 4 )] was self-applied by volunteers for 2 wk. No significant variations in urinary iodide, TSH, and serum (total and free) T 4 and T 3 concentrations were observed at any time relative to pretreatment values, whereas rT 3 concentrations increased significantly 6 and 12 h after cream application. The increased rT 3 concentration led us to investigate the presence of inner ring type III deiodinase (D3) activity in human skin. Using human surgical discard skin, we found that T 4 can be carried across human epidermis in a liposome cream. Substantial inner ring deiodination was suggested by the fact that only 10% of transferred thyroid hormone remained as T 4 , and T 3 was not detected. We then measured D3 activity in a surgical skin specimen. The K m for T 3 was 1.74 nmol/liter, and the maximum velocity was 23.5 fmol/g microsomal protein/h. In conclusion, our study indicates that normal human skin serves as a substantial, but incomplete, barrier to T 4 passage. 
C REAMS CONTAINING LARGE amounts of thyroid
hormone are employed for cosmetic purposes to reduce deposits of sc adipose tissue. Thyroid hormone accelerates lipid degradation, and this is the rationale for their administration. l-T 4 [3,5,3Ј,5Ј-tetraiodothyronine (T 4 )] is the major secretory product of the thyroid gland. T 4 per se has little biological activity, but is converted to the active form by deiodinases that remove an iodide from the outer ring of the molecule, producing T 3 (1) (2) (3) (4) (5) . The reaction occurs mainly in extrathyroidal tissues and is catalyzed by two deiodinase enzymes (D1 and D2). A third deiodinase enzyme (D3) selectively deiodinates the inner ring of T 4 and T 3 leading to inactive metabolites, rT 3 and 3,3Ј-diiodothyronine (3,3Ј-T 2 ), respectively. To our knowledge, there are no data in the literature concerning the percutaneous absorption of thyroid hormone in humans or the role of human skin in the metabolism of thyroid hormone. This study was undertaken to determine whether T 4 applied to the skin surface could be absorbed and enter the bloodstream either directly or as a deiodinated iodothyronine metabolite.
Subjects and Methods

Experiment 1
Nine volunteer healthy female subjects (age range, 32-39 yr) entered the study. Thyroid disease was excluded by ultrasound examination, hormone assays, and tests for antithyroid antibodies. Following instructions from the manufacturer, 20 ml cream containing 20 mg l-T 4 (Somatoline, Manetti & Roberts, Florence, Italy) were applied on d 1, followed by 10 ml/d for 2 wk. At 0800 h each day, subjects applied the thyroid cream to abdominal and thigh skin. The cream requires 20 min for complete absorption. Blood samples were obtained at 0800 h the day before applying the cream; 6, 12, and 24 h after the first application; and on d 15, 24 h after the last application. Serum was assayed for total T 4 , free T 4 , total T 3 , free T 3 , TSH, and rT 3 . Urinary iodide was measured in a morning sample obtained the day before starting the treatment and 24 h after the last cream application. Informed consent was obtained from all volunteers.
Experiment 2
Two months after the first experiment, six healthy female volunteers from the original group self-administered 30 ml l-T 4 cream. Blood was drawn before and 3, 6, 12, and 24 h after the application. Serum samples were processed as described for experiment 1.
To measure physiological variations in serum TSH and rT 3 concentrations, serum samples were obtained from six additional volunteers who did not use the l-T 4 cream. Samples were drawn at 0800, 1100, 1400, and 2000 h for measurements of serum TSH and rT 3 .
Chromatographic analysis of somatoline
To confirm that the cream contained T 4 , but not T 3 or rT 3 , a sample of the cream was analyzed by reverse phase HPLC. Ten grams of cream were dissolved at 60 C in 100 ml 0.1 n methanolic hydrochloric acid. The resulting mixture was cooled to 0 C and then filtered using first filter paper (no. 1, Whatman, Clifton, NJ) and then an Acrodisc LC (polyvinylidene difluoride, 0.45 m) filter. Analytical HPLC analysis was performed on a Beckman System Gold apparatus (Fullerton, CA) under the following conditions: Beckman Ultrasphere Ods 5 column (4.6 mm ϫ 25 cm); eluant A, methanol/phosphoric acid (100:0.2, vol/vol); eluant B, water/phosphoric acid (100:0.2, vol/vol); gradient from 50 -65% A over 22 min; flow, 2.0 ml/min; UV detection, 230 nm (6) . 
Hormone assays
Test transdermal cream to demonstrate transcutaneous diffusion
T 4 diffusion assessment
Epidermal samples taken from human surgical discards were drawn across Franz Diffusion Cell (TheraTech, Inc., Salt Lake City, UT) lumens according to the manufacturer's instructions. Epidermal samples so placed separated tested substances from small reservoirs of 0.9% saline. The withdrawn samples from the reservoirs below radiolabeled substances and controls were counted in a ␥-counter. The withdrawn samples from the reservoirs below cold T 4 samples and controls were subjected to measurement of total T 4 and total T 3 using standard RIA kits (ICN Biomedicals, Inc., Orangeburg, NY). Customized standards were designed with known concentrations of each hormone in saline. Each condition was repeated with four randomly selected skin samples.
Measurement of D3 activity
A skin specimen was obtained from a 13-yr-old girl who underwent plastic surgery for an ectopic breast, and D3 activity was determined by measuring the conversion of T 3 to 3,3Ј-T2 as previously described (10) . T 3 is the favorite physiological substrate for D3, and using T 3 as a substrate for the 5-monodeiodinase assay makes the assay more sensitive and precise than when T 4 is used. For this reason we preferred to use T 3 instead of T 4 for measurement of D3 activity in skin. The sample was homogenized in 50 mmol/liter phosphate buffer (pH 7.4) containing 10 mmol/liter EDTA and 0.4 mmol/liter phenylmethylsulfonylfluoride (Sigma-Aldrich Corp., St. Louis, MO). Microsomes were prepared by ultracentrifugation and suspended in the same buffer by sonication. The protein concentration was determined using a microassay reagent (Bio-Rad Laboratories, Inc., Richmond, CA). Microsomes (5-40 g protein) were incubated with [
125 I]T 3 (0.6 -2.4 nmol/liter; Amersham International, Milan, Italy) in the presence of dithiothreitol (10 mmol/liter; Sigma-Aldrich Corp.), in 0.1 mol/liter Tris buffer, pH 7.4, at 37 C for 30 to 240 min (final volume, 0.25 ml). The reaction was stopped by adding 0.1 ml 5% BSA, followed by 2 vol ethanol. The mixture was centrifuged and [
125 I]3,3Ј-T2 was quantified in an aliquot (75 l) of the supernatant by binding to a highly specific rabbit anti-3,3Ј-T2 antibody in a 16-h incubation at 4 C. The antibody bound [ 125 I]3,3Ј-T2 was precipitated by adding a previously determined excess of goat antirabbit ␥-globulin.
Statistical analysis
Data for D3 activity are reported as the mean of duplicate determinations that differed from each other by less than 10%. Other data are reported as the mean Ϯ sd. Variables were compared with controls using t test and ANOVA.
Results
Experiment 1
After 2 wk of treatment with l-T 4 -containing creams, urinary iodide did not change significantly relative to pretreatment values (posttreatment, 77.8 Ϯ 16 g/g creatinine; pretreatment, 48.1 Ϯ 10.3 g/g creatinine; P Ͼ 0.05). T 4 and T 3 concentrations did not change significantly during the treatment period. rT 3 concentrations increased significantly 6 and 12 h after cream application (Fig. 1) . Serum TSH concentrations exhibited a circadian rhythm in subjects receiving l-T 4 cream, which was similar to that observed in controls not receiving the l-T 4 -containing cream (Fig. 2) . Further, serum TSH measured after 2 wk of cream application did not differ from pretreatment values. No significant intraday variation of rT 3 concentration was observed in controls not applying the l-T 4 cream (data not shown).
Experiment 2
After a single cutaneous application of 30 mg l-T 4 , no changes in serum T 4 or T 3 concentrations were observed. A significant increase in serum rT 3 was seen 6 and 12 h after l-T 4 application (Fig. 3) . No changes in the TSH rhythm were observed relative to controls (Fig. 4) .
A liposome cream can transport thyroid hormone across human epidermis
Samples taken from Franz cells treated with [
125 I]T 4 in saline, saline alone, and liposome vehicle alone did not have significantly different quantities of radioactivity measured with the ␥-counter. In contrast, significantly more radioactivity was detected in samples taken from Franz cells treated with [
125 I]T 4 in the liposome vehicle (Fig. 5) . At 2 h, radioactivity equal to 4.3 Ϯ 0.4% of the original sample (P Ͻ 0.005) was observed. The activity equaled 5.4 Ϯ 1.4% of the original sample at 4 h (P Ͻ 0.01) and 10.2 Ϯ 3.4% of the original sample at 24 h (P Ͻ 0.05). Total T 3 was not detectable at any time point under any tested condition. The detection limit of the T 3 assay was 1% of the compound transferred or 0.1% of the original compound applied. Over the course of the experiment, total T 4 concentrations represented 10.5 Ϯ 4% (P Ͻ 0.05) of the total compound transferred (or ϳ1% of the original compound).
Characterization of D3 activity in human skin
The increase in the serum rT 3 concentration, without a concomitant rise in serum T 4 concentration, led us to investigate and characterize the presence of inner ring deiodinating activity in human skin. A specimen from breast skin of a young woman was tested for D3 activity immediately after surgical resection. D3 activity increased with enzyme content up to 40 g microsomal protein and with incubation time up to 240 min (Fig. 6 ). Figure 7 shows the kinetic parameters of 5-monodeiodination of T 3 by Lineweaver-Burk analysis. The K m was 1.74 nmol/liter, and the maximum velocity was 23.5 fmol/g microsomal protein⅐h. (Fig. 8a) contained a well resolved peak corresponding to T 4 , and did not show any appreciable peaks at the retention times corresponding to T 3 and rT 3 .
Establishment of L-T 4 cream purity
Discussion
The widespread use of T 4 -containing creams for cosmetic purposes has raised concern of possible systemic side-effects due to the percutaneous absorption of the hormone (11). T 4 per se has little biological effect, because it is a poor ligand for thyroid hormone receptors. Enzymatic outer ring deiodination of T 4 leads to activation of the molecule by transforming it to the much more potent T 3 . T 3 can act locally within the tissue where it is produced or systemically through the bloodstream. Inner ring deiodination of T 4 and T 3 leads to the inactive metabolites rT 3 and 3,3Ј-T 2 , respectively. Sequential monodeiodination of various iodothyronines and conjugation with glucuronic acid or sulfuric acid complete the metabolism of the hormone (1-5).
Our study was conducted by topically applying amounts of T 4 that greatly exceed the physiological production rate in humans. Indeed, when such high doses are taken orally they produce overt thyrotoxicosis. In contrast, the measurement of serial serum samples after skin application of T 4 to our volunteers did not show any significant change in concen- Skin provides a barrier between the body and the environment, arresting the penetration of microorganisms or destructive chemicals, absorbing radiation from the sun, and preventing the loss of fluids (12, 13) . The primary compartment that limits the percutaneous absorption of compounds is the stratum corneum, a highly differentiated structure made of "bricks" of bundled, water-insoluble proteins (the corneocytes) embedded within a continuous lipid-rich matrix. It is mainly through intercellular lipid that skin allows some permeation of almost every substance, although rates of penetration of different materials may vary by several thousand fold. Skin contains a wide range of enzymatic activity, including oxidative, reductive, hydrolytic, and conjugative reactions, as well as a full complement of drugmetabolizing enzymes (14) . Eventually, the extent of blood flow regulates resorption of compounds by the cutaneous microvasculature (15) . Thus, to undergo percutaneous absorption, a compound must penetrate the stratum corneum, diffuse through the viable epidermis into the dermis, and gain access to the systemic compartment through the vascular system.
We investigated the mechanisms making the human skin a barrier to T 4 , as the hormone could be either blocked on the skin surface or metabolized before entering the bloodstream. Ten milligrams of T 4 contain approximately 6.5 mg iodide that would be mostly removed from the molecule by T 4 metabolizing enzymes once T 4 had entered the bloodstream. Although the metabolic clearance rate of T 4 is slow, its serum half-life approximating 7 d, the iodide contained in a daily dose of T 4 administered for 2 wk would saturate the thyroid and appear in the urine. In our volunteers, urinary iodide concentrations did not change significantly relative to measurements preceding T 4 administration. These data suggest that the majority of T 4 applied on the skin surface did not reach the deepest layers where it could be either metabolized or enter the circulation. We did demonstrate a clear increase in serum levels of rT 3 6 -12 h after T 4 application. Circulating rT 3 is cleared about 120 times faster than T 4 . Therefore, the rise in serum rT 3 without a concomitant rise in serum T 4 suggests that some T 4 did cross the external layers of the skin. but was inner ring deiodinated before reaching the bloodstream.
In our analysis we sought to confirm that thyroid hormone could be transported transcutaneously in an appropriate vehicle. To that end, thyroid hormone was introduced into liposome cream (see Subjects and Methods). The experiment confirmed that a simple liposome cream facilitated thyroid hormone transfer. Using 0.9% saline as a vehicle, T 4 did not cross the epidermis in significant quantities. When liposome cream was used as a vehicle, T 4 was consistently transported in measurable quantities. Substantial inner ring deiodination was suggested by the fact that only 10% of transferred thyroid hormone remained as T 4 , and T 3 was not detected.
To test the hypothesis that the human skin contains iodothyronine inner ring deiodinase activity, we characterized D3 enzyme activity in a skin specimen from a young woman. The results indicate that iodothyronine inner ring deiodinase activity was abundant, with an affinity constant comparable to those of the iodothyronine inner ring deiodinases in placenta and brain (16, 17) , thus confirming that conversion of T 4 to rT 3 occurs in skin tissue. The specific iodothyronine inner ring deiodinase D3 has been previously detected in human placenta, brain, and liver (10, (17) (18) (19) (20) (21) . D3 has also been detected in skin and gut in other species (22, 23) . The cDNA for a selenoprotein with the kinetic properties of D3 has been isolated in the human placenta, and the corresponding mRNA has been detected in both placenta and lung (24) . D3 causes irreversible degradation of T 4 and T 3 . T 3 is the preferred substrate for D3. Recent studies indicate that D3 is responsible for the differential regulation of T 3 levels in selected tissues, such as brain, by interplay with the activating deiodinases D1 and D2 (17, (25) (26) (27) . In fetal life, D3 keeps serum T 3 levels low while maintaining high levels of rT 3 (28) . Placental D3 also plays a role in limiting the passage of maternal T 3 to the fetus (29 -31) . D3 activity has been detected in the fetal rat skin (22) . Our data suggest that skin D3 may contribute to limiting fetal transdermal passage of maternal thyroid hormone present in the amniotic fluid.
Our experiments used thigh skin for the in vivo studies and surgical breast skin discards for the in vitro studies. Relative thyroid hormone transfer may differ for skin in other regions of the body. Although our study is reassuring regarding general risks of cutaneous T 4 administration, the degree of danger is not known in situations compromising the barrier function of the skin for T 4 . The skin barrier may be altered in pathological conditions that alter the structure of the stratum corneum (13, 14) , including environmental conditions and physical trauma. Agents affecting the permeability of skin may also influence its barrier function. Thus, the use of keratolitics or fat solvents may allow increased T 4 penetration through the skin by disrupting the epidermal barrier. Tape stripping of the skin has also been shown to disrupt the stratum corneum barrier (32) . Further, total blood flow in skin may vary up to 100-fold, a process primarily regulated by vascular shunts as well as by recruitment of new capillary beds (15) . Thus, changes in temperature, sun exposure, or vasoactive compounds may influence skin blood flow and percutaneous absorption of exogenous compounds. We therefore suggest caution with the use of large doses of T 4 applied to the skin, particularly in patients with concomitant skin disease or traumatic injuries.
In conclusion, our study indicates that the normal human skin serves as a substantial barrier to T 4 passage from the outside surface, with D3 playing an important role in this function by inactivating T 4 to rT 3 .
